Functional tissue engineering of the liver and islets

The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology
Kazuo Ohashi, Teruo Okano

Abstract

Cell-based therapies by using hepatocytes and islets have recently been evaluated as a new therapeutic modality for patients with many forms of liver diseases and insulin-deficient diabetes mellitus. In most of the recently conducted clinical trials, cells have been delivered into liver vasculatures by infusing them through the portal circulation. More recently, tissue engineering-based approaches have spurred significant interests, using hepatocytes and islets in which small but functional new tissues would be created in vivo. Under circumstances in which a higher level of cell engraftment could be obtained, these approaches could provide therapeutic effects. Considerable efforts have been given to sustaining engineered tissues and maintaining their therapeutic effects. This review highlights several strategies that can achieve a higher level of cell survival for creating new functional liver and islet tissues.

References

Oct 16, 2002·Nature Biotechnology·Eric C OlivaresMichele P Calos
Nov 20, 2002·Comparative Hepatology·Filip Braet, Eddie Wisse
Dec 25, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuo OhashiMark A Kay
Jan 26, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·T YokoyamaY Nakajima
Jan 28, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yaakov NahmiasMartin L Yarmush
Jan 20, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Melanie F BrownJeffrey A Stuart
Mar 3, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eri MukaiHiroyuki Mizuguchi
Jun 15, 2007·Journal of Cellular Physiology·George K Michalopoulos
Sep 1, 2007·Biomaterials·Joseph YangTeruo Okano
Mar 13, 2008·Tissue Engineering. Part a·Alton M HiscoxStuart K Williams
Jun 25, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·S W PipeD Lillicrap
Sep 30, 2008·Diabetes·Nathalie M Fiaschi-TaeschAndrew F Stewart
Nov 11, 2008·The British Journal of Surgery·S MeraniA M J Shapiro
Nov 13, 2008·Cytotechnology·Susan Fugett Abu-AbsiWei-Shou Hu
Jan 8, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Kazuo Ohashi
Mar 27, 2009·Tissue Engineering. Part a·Masakazu InamoriToshihisa Kajiwara
Apr 24, 2009·Tissue Engineering. Part a·Shohta KodamaCharles A Vacanti
Jun 30, 2009·Tissue Engineering. Part a·Alan J HusseySandra J Feeney
Feb 27, 2010·Diabetes·Domenico BoscoThierry Berney
Oct 1, 2010·Advanced Materials·Joseph YangTeruo Okano
Oct 6, 2010·Journal of Diabetes Science and Technology·Jaime A GiraldoCherie L Stabler
Nov 13, 2010·Gastroenterology·Toshitaka HoppoEric Lagasse

❮ Previous
Next ❯

Citations

Feb 10, 2016·Cell Medicine·Shingo YamashitaMasakazu Yamamoto
Sep 22, 2017·Current Transplantation Reports·Kohei Tatsumi, Teruo Okano
May 23, 2017·Tissue Engineering and Regenerative Medicine·Fatemeh AleahmadTahereh Talaei-Khozani
Jan 9, 2020·BioMed Research International·Germán R Jiménez-GastélumErika L Silva-Benítez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Hepatology Research : the Official Journal of the Japan Society of Hepatology
Kazuo Ohashi
World Journal of Surgery
A BokerR Alejandro
Current Pharmaceutical Biotechnology
Bijoy Chandapillai Karikkineth, Wolfram-Hubertus Zimmermann
Molecular and Cellular Endocrinology
Hans E Hohmeier, C B Newgard
© 2021 Meta ULC. All rights reserved